• jonanne
    $ADMP They need euro & asian post POC raise to have cash both to phase 3 taper & launch epi w/o secondary. Iffy.
    6/17/14
    Reply (26)
    • hikeleader: $7,000,000 isn't enough? Why not launch epi and then fund phase three with revenue from epi?
      6/17/14
    • jonanne: 10 months burn between now and then including the POC and g&a, they talk about hiring a sales force instead of using a CSO,
      6/17/14
    • jonanne: they need working capital to finance sales. Not possible on $7Million.
      6/17/14
    • hikeleader: Their burn is $250,000/month
      6/17/14
    • homerun: Highly unlikely dilution will be a problem before POC results at current burn rates.
      6/17/14
    • homerun: $ADMP is an easy double before any dilution will happen. The big question is whether or not they get a partner post POC.
      6/17/14
    • homerun: Personally, I don't see why $TEVA doesn't jump all over this post POC. I could be wrong...
      6/17/14
    • jonanne: That's my point, either they need partners post POC or secondary. They aren't going to finance POC, a sales force and epi launch on $4.5 Mil
      6/17/14
    • hikeleader: They stated very clearly on the CC that following POC on the Advair product that they would pursue partners in Japan and Europe.
      6/17/14
    • jonanne: And if they aren't able to secure sufficient $s to launch epi and p3 the Taper there will be a secondary.
      6/17/14
    • jonanne: What they should do is a public sub ipo on the pharma div. which would give the specialty div. capital and allow the ca drugs to progress
      6/17/14
    • jonanne: Ignoring the pharma division raises questions, even at the ethical level.
      6/17/14
    • hikeleader: If......so not a certainty....Or they just use epi income to fund trials.
      6/17/14
    • jonanne: Instead promising ca drugs sit on the shelf.
      6/17/14
    • jonanne: That structure would not be diluitive.
      6/17/14
    • jonanne: as to the specialty drugs and there is no activity on the ca drugs so what would be diluted ius presently non-existent.
      6/17/14
    • hikeleader: How do you know that?
      6/17/14
    • hikeleader: Per CRT Capital: They have a $15 target: ADMP currently has no revenues, and may require additional funds to continue operations in future.
      6/17/14
    • hikeleader: We estimate the Company to burn through most of its $7 million of cash in 2014,
      6/17/14
    • hikeleader: potentially requiring additional funds to be raised by early 2015. Potential additional sources of cash could be obtained if
      6/17/14
    • hikeleader: Adamis is successful in securing partnerships for its respiratory/allergy treatments.
      6/17/14
    • hikeleader: In addition, the Company may look to spin out its existing biotechnology pipeline.
      6/17/14
    • homerun: Even if $ADMP announces a secondary minus a partner after POC, you better have some dry powder because that will be a wonderful entry point
      6/17/14
    • homerun: Of course, I am assuming the POC trial will be a success. If that's the case, the stock should be well above the current pps.
      6/17/14
    • homerun: If they raise 15-20 million at 10 bucks, after a successful POC trial, we have an 8 dollar stock. Risk/reward is favorable right now IMHO.
      6/17/14
    • homerun: I love the trade right here in $ADMP with heavier downside volume but I'm playing $CUR right now.
      6/17/14